TELEFLEX INC (TFX): Results of Operations and Financial Condition
TELEFLEX INC (TFX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 6, 2026 Teleflex Reports Second Quarter Finan cial Results and Full Year 2026 Outlook Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock Announces $250 Million Accelerated Share Repurcha
How this was made
The 30-second read
Why it matters
Key trading inputs are the guidance reductions (GAAP revenue growth and GAAP EPS) alongside an increase in adjusted diluted EPS, plus a scheduled $250M accelerated share repurchase and refinancing/debt actions. Product/regulatory and clinical pipeline updates (EZPLAZ BLA approval, Freesolve trial milestones) add longer-horizon optionality but are secondary to the near-term guidance and integration timing.
Market read
This is a decision-grade update combining earnings/guidance, a scheduled buyback tranche, and a stated reason for revenue outlook pressure (Biotronik integration taking longer).
What to watch
The guidance assumptions explicitly include transition services margin and exclude certain items (tariff refunds, discontinued operations), so traders should normalize comparisons to continuing-ops and adjusted metrics before extrapolating.
Teleflex reported second-quarter continuing-operations revenue of $570.3 million, completed the OEM divestiture for $1.5 billion in cash, repurchased $250 million of common stock, reduced its 2026 revenue outlook, and increased its adjusted diluted EPS outlook.
Revenue from continuing operations rose 28.9% as Vascular and Surgical each grew, while pro forma adjusted constant currency revenue growth was 4.7% and Interventional pro forma adjusted constant currency revenue declined 1.0%. GAAP diluted EPS from continuing operations declined to $0.96, although adjusted diluted EPS increased to $1.76. The company reduced full-year revenue and GAAP EPS outlook while increasing adjusted diluted EPS outlook.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue from continuing operationsGAAP | $570.3 million | – | 28.9% |
| Pro forma adjusted revenue from continuing operationsother | $570.3 | – | 23.8% |
| Pro forma adjusted constant currency revenue growth from continuing operationsother | 4.7% | – | – |
| GAAP diluted EPS from continuing operationsGAAP | $0.96 | – | – |
| Adjusted diluted EPS from continuing operationsnon-GAAP | $1.76 | – | – |
| Revenue from continuing operations, six months ended June 30, 2026GAAP | $1,118.6 | – | 30.6% |
| Pro forma adjusted revenue from continuing operations, six months ended June 30, 2026other | $1,118.6 | – | 23.9% |
| Pro forma adjusted constant currency revenue growth from continuing operations, six months ended June 30, 2026other | 4.9% | – | – |
| Depreciation expense, amortization of intangible assets and deferred financing charges, six months ended June 30, 2026GAAP | $106.5 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| VascularPro forma adjusted constant currency revenue growth was 8.0%. | $246.3 | – | 9.0% |
| InterventionalReported revenue included 87.3% adjustment impact; pro forma adjusted constant currency revenue growth was (1.0)%. | $211.9 | – | 86.1% |
| SurgicalPro forma adjusted constant currency revenue growth was 9.2%. | $112.1 | – | 9.1% |
full year 2026 continuing operations outlook
- Revenue$2,260 to $2,280
- NoteGAAP revenue growth: 13.40% to 14.40%.
- NotePro forma adjusted constant currency revenue growth: 3.50% to 4.50%.
- NoteGAAP diluted earnings per share from continuing operations: $2.54 to $2.84.
- NoteAdjusted diluted earnings per share from continuing operations: $6.90 to $7.20.
- NoteApproximately 19% adjusted operating margin for 2026 inclusive of transition services associated with the close of the OEM Strategic Divestiture.
- NoteIncludes an estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations.
- NoteAdjusted diluted EPS guidance reflects $250 million of share repurchase activity in the second quarter of 2026 and pay off of ~$700 million Term Loan A-2.
- NoteAdjusted diluted EPS guidance excludes expected benefits from transition services and manufacturing services agreements upon closing the Acute Care and Interventional Urology Strategic Divestiture.
- NoteAdjusted diluted EPS guidance excludes the impact of the announced $250 million Accelerated Share Repurchase and other anticipated future repurchases under the previously announced $1 billion share repurchase program.
- NoteAdjusted diluted EPS from continuing operations excludes any impact of potential IEEPA tariff refunds.
Capital returns
- The OEM business was divested to Montagu and Kohlberg for $1.5 billion in cash.
- The company estimates after-tax proceeds of approximately $1.25 billion.
- The company paid off its $700 million Term Loan A-2 associated with the acquisition of substantially all of Biotronik's Vascular Intervention business.
- The Board of Directors authorized a share repurchase program for up to $1 billion of common stock on December 9, 2025.
- During the second quarter, the company repurchased 1.9 million shares of common stock for $250 million through open market transactions at an average price per share of $130.85.
- As of June 30, 2026, $750 million remained available under the authorization.
- The company intends to commence an accelerated share repurchase of $250 million of common stock, effective August 7, 2026.
What drove it
- Vascular reported revenue growth of 9.0% and pro forma adjusted constant currency revenue growth of 8.0%.
- Surgical reported revenue growth of 9.1% and pro forma adjusted constant currency revenue growth of 9.2%.
- Interventional reported revenue growth of 86.1%, with 87.3% adjustment impact and pro forma adjusted constant currency revenue growth of (1.0)%.
- Teleflex received BLA approval from the U.S. Food and Drug Administration for EZPLAZ™ Freeze Dried Plasma in late July.
- The company completed enrollment ahead of schedule in the BIOMAG-II study and initiated the U.S. BIOMAG-III pivotal trial, with first patient procedures completed in June at MedStar Washington Hospital Center.
Concerns
- Integration of the acquired Biotronik Vascular Intervention business is progressing more slowly than expected.
- The company said elongated integration timelines, rather than the underlying product portfolio, drove the updated revenue outlook.
- Full-year 2026 GAAP revenue growth guidance was reduced to 13.40% to 14.40%.
- Full-year 2026 pro forma adjusted constant currency revenue growth guidance was reduced to 3.50% to 4.50%.
- Full-year 2026 GAAP diluted EPS from continuing operations guidance was reduced to $2.54 to $2.84.
- GAAP diluted EPS from continuing operations was $0.96 compared to $1.54 in the prior-year period.
What to watch
- Execution of mitigation actions addressing the primary drivers of the Biotronik Vascular Intervention integration delay.
- Interventional pro forma adjusted constant currency revenue growth, which was (1.0)% in the second quarter.
- Completion of the $250 million accelerated share repurchase effective August 7, 2026 and additional repurchases under the $1 billion authorization.
- Closing of the Acute Care and Interventional Urology Strategic Divestiture and the expected transition services and manufacturing services agreements.
- The BIOMAG-II data readout positioned for late 2027.
- Progress toward the approximately 19% adjusted operating margin assumption for 2026 inclusive of transition services associated with the OEM Strategic Divestiture.
Balance sheet and cash flow
- Total cash, cash equivalents and restricted cash equivalents at June 30, 2026 were $316.9 million compared to $402.7 million at December 31, 2025.
- Net accounts receivable at June 30, 2026 were $364.6 million compared to $345.6 million at December 31, 2025.
- Inventories at June 30, 2026 were $351.9 million compared to $404.4 million at December 31, 2025.
- The new credit agreement provides for a $1 billion revolving credit facility and a $500 million term A-1 loan facility, both maturing on May 26, 2031, and a $700 million term A-2 loan facility maturing on May 26, 2028.
- The company completed a private offering of $500 million aggregate principal amount of 5.875% senior notes due 2032.
- The company used net proceeds from the notes offering, together with cash on hand, to redeem all outstanding 4.625% Senior Notes due 2027.
Analysis
Teleflex reported second-quarter revenue from continuing operations of $570.3 million, up 28.9% from the prior-year period. On the company’s pro forma adjusted constant currency basis, revenue growth was 4.7%. Vascular revenue was $246.3 and grew 9.0%, while Surgical revenue was $112.1 and grew 9.1%. Interventional revenue was $211.9, with reported growth of 86.1%, but its pro forma adjusted constant currency revenue growth was (1.0)% after the stated adjustments.
Earnings presented a split result. GAAP diluted EPS from continuing operations was $0.96, compared with $1.54 in the prior-year period. Adjusted diluted EPS from continuing operations was $1.76, compared with $1.73. The filing does not provide quarterly gross margin, operating income, net income, operating cash flow, or free cash flow in the supplied text, limiting assessment of the operating-income and cash-conversion bridge.
The company completed the sale of its OEM business for $1.5 billion in cash and estimates after-tax proceeds of approximately $1.25 billion. It paid off its $700 million Term Loan A-2 and repurchased 1.9 million shares for $250 million during the quarter. Teleflex also announced a $250 million accelerated share repurchase effective August 7, 2026, with $750 million remaining under the existing authorization as of June 30, 2026. Separately, it refinanced its credit agreement and issued $500 million aggregate principal amount of 5.875% senior notes due 2032.
The full-year outlook was reduced for GAAP revenue growth, pro forma adjusted constant currency revenue growth, and GAAP diluted EPS. The company set GAAP revenue guidance at $2,260 to $2,280 and adjusted diluted EPS guidance at $6.90 to $7.20. Management attributed the revenue outlook change to elongated integration timelines for the acquired Biotronik Vascular Intervention business and said the underlying product portfolio remains competitively well positioned.
Product-development activity included FDA BLA approval for EZPLAZ in late July, completed BIOMAG-II enrollment ahead of schedule, and initiation of the U.S. BIOMAG-III pivotal trial. The principal operating item to monitor is whether integration mitigation actions restore Interventional pro forma adjusted constant currency growth while the company executes its debt reduction, divestiture, and repurchase plans.
Management, verbatim
We delivered a strong second quarter, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to strengthen the company for the future.
Jason Weidman, President and Chief Executive Officer
Integration of the acquired Biotronik Vascular Intervention business is progressing, though taking longer than expected, and we updated our revenue outlook accordingly.
Jason Weidman, President and Chief Executive Officer
I’m encouraged by the progress our team is making across the organization. Looking ahead, I am focused on completing a thorough assessment of the business and sharpening our strategic and operating plan to maximize shareholder value.
Jason Weidman, President and Chief Executive Officer
Not in the filing
stated, not guessed- Quarterly GAAP gross profit and gross margin.
- Quarterly adjusted gross profit and adjusted gross margin.
- Quarterly GAAP operating income or loss and operating margin.
- Quarterly adjusted operating income or loss and adjusted operating margin.
- Quarterly GAAP net income or loss from continuing operations.
- Quarterly adjusted net income or loss from continuing operations.
- Quarterly operating cash flow.
- Quarterly free cash flow.
- Dividend amount and dividend payment details.
- Total debt balance at June 30, 2026.
- Net debt balance at June 30, 2026.
- Quarterly tax rate and adjusted tax rate.
- Prior-quarter comparisons for revenue, segment revenue, EPS, and other operating metrics.
- Prior outlook section for comparison with reported results.
- Full reconciliation tables beyond the truncated filing text.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Teleflex filed an SEC 8-K with Q2 2026 results for continuing operations, updated 2026 outlook, and capital allocation updates following completion of its OEM divestiture.
Ticker impact
Teleflex reported Q2 results and cut 2026 GAAP revenue and EPS guidance while raising adjusted EPS, plus announced a $250M accelerated buyback starting Aug 7.
Moderate volatility around the guidance cut and buyback details; upside bias if investors focus on adjusted EPS increase and OEM proceeds/deleveraging.
The filing contains multiple decision-relevant datapoints: Q2 continuing-ops revenue/EPS, updated 2026 guidance ranges, OEM divestiture proceeds and term-loan payoff, and a scheduled accelerated repurchase effective Aug 7. The main uncertainty is the longer-than-expected Biotronik integration delay, which directly affects the revenue outlook.
Market effects
Could influence sentiment for medical device peers via read-through on vascular/surgical demand and integration execution risk.
Primarily US-listed large-cap medtech sentiment; limited direct regional spillover.
FDA approval (EZPLAZ) and ongoing scaffold trial progress may support broader global medtech innovation narratives, but the dominant driver is company-specific guidance.
Counterpoint
Investors may over-discount the revenue outlook cut if adjusted EPS guidance rises and OEM proceeds plus deleveraging improve earnings quality and flexibility.
Key entities
- companyTeleflex Incorporated
Reported Q2 2026 continuing-operations results, updated 2026 guidance, completed OEM divestiture, and announced a $250M accelerated share repurchase.
- counterpartyMontagu and Kohlberg
Buyers of Teleflex's OEM business for $1.5B cash, generating proceeds used for debt reduction and capital return.
- regulatorU.S. Food and Drug Administration
Approved Teleflex's EZPLAZ Freeze Dried Plasma BLA in late July.
